CJC-1295 DAC

CJC-1295 is a long acting GHRH analog. Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF or GHRF) or somatocrinin is a 44-amino acid peptide hormone produced in the hypothalamus by the arcuate nucleus. GHRH stimulates growth hormone (GH) secretion from the pituitary. GHRH is released in a pulsatile manner, stimulating pulsatile release of GH respectively.

In addition, GHRH also promotes slow-wave sleep.

It has the ability to bioconjugate with serum albumin to increase its half life and therapeutic window.
CJC-1295 helps in promoting slow wave sleep. It is also known as deep sleep which is the part of sleep responsible for maximum muscle growth and memory retention level.
Also it is beneficial in treating visceral fat deposits in obese AIDS patients and increasing levels of exogenous HGH to increase fat loss.

The active portion of this GRF or GHRH peptide can be found as a 29 amino acid long peptide and is appropriately named GHRH1-29. This pulsatile release of various peptides is due to the negative feedback loop that is part of the HGH axis and controls the amount of HGH that your body produces to keep it in a homeostatic environment. Despite the effectiveness of GHRH to stimulate growth hormone release there are a number of problems associated with using it in vivo.

Molecular Formula: C165H269N47O46
Molecular Weight: 3647.15
CAS No. : 863288-34-0
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(maleimido)
For RESEARCH PURPOSES ONLY

CJC-1295 is a tetra substituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog. One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.
Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hGH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects.

CJC-1295 is a tetrasubstituted peptide analogue of GHRH with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, position 15 to enhance bioactivity, and position 27 to prevent methionine oxidation. These substitutions are key in increasing the overall half life of CJC-1295 but there lies an even greater reason as to why the half life has been extended from ~7 minutes to greater than 7 days! Bioconjugation is a relatively newer technology that takes a reactive group and attaches it to a peptide, which in turn reacts with a nucleophilic (usually a partially negative molecule) entity found in the blood to form a more stable bond. Albumin, one of the most abundant substances in the human body is chosen as the nucleophile by this particular peptide thanks to a Cys34 thiol group that attracts it. By combining the tetrasubstituted GHRH analogue with maleimodoproprionic acid using a Lys linker, you create a GHRH peptide with a high binding affinity for albumin. Once the CJC-1295 molecule has attached itself to albumin, it is given an extended half life and bioavailability thanks to the albumin preventing enzymatic degradation and kidney excretion. In fact, bioconjugation is so effective that there was less than 1% of CJC-1295 left unreacted in vivo and over 90% was stabilized after subQ admin. This means that you get more of what you paid for working for you. There was no DPP-IV degradation observed on CJC-1295 in any of the various experiments conducted.

Due to the extremely long half-life of CJC-1295 it is plausible for researchers to use this peptide once per week with outstanding results. Various experiments have been conducted to test the effectiveness of CJC-1295 in vivo and the Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection! Not only that but they proved the mean half-life to be 5.8-8.1 days and after multiple doses showed mean IGF-1 levels remained above baseline for up to 28 days following! No serious adverse reactions were reported in any group.

Another very positive benefit of CJC-1295 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS is decreased significantly in older adults and also with people who tend to exercise later in the evening. This peptide has a benefit to side effect ratio that exceeds all others currently being legally sold and would make a great addition to one’s training regimen or post cycle therapy.

Various experiments have been conducted to test the effectiveness of CJC-1295. The Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days. The mean half life was 5.8-8.1 days and after multiple doses mean IGF-1 levels remained above baseline for up to 28 days following. No serious adverse reactions were reported in any group participating in this research study. This peptide has the ability to stimulate growth hormone very significantly.

Another very positive benefit of CJC-1295 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS are decreased significantly in older adults and also with people who tend to exercise later in the evening. Clinical studies have shown that a once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH can induce significantly deeper sleep in a mouse.

CJC- 1295

CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone invented by ConjuChem, a biotechnology company in Canada. CJC-1295 primarily functions as a growth hormone releasing hormone analog. The way these peptides are engineered, its half life has been increased from a less as 7 minutes to greater than 7 days. Protecting groups around the amino acids of GHRH which are liable to enzymatic reaction are used to accomplish this life. With extremely long half life, the use of CJC-1295 once per weak is quite reasonable to get outstanding results. ½ dosages twice in a week are ideal to keep serum levels high. Also CJC-1295 peptide is helpful in promoting deep sleep which is a portion of sleep responsible for maximum muscle growth and retention.

2 mg / vial

CJC- 1295